Letter to the editor: l-ornithine l-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial
- PMID: 35788964
- DOI: 10.1002/hep.32643
Letter to the editor: l-ornithine l-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial
Comment on
-
L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.Hepatology. 2022 May;75(5):1194-1203. doi: 10.1002/hep.32255. Epub 2021 Dec 21. Hepatology. 2022. PMID: 34822189 Clinical Trial.
References
REFERENCES
-
- Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, et al. l-ornithine l-aspartate in acute treatment of severe hepatic encephalopathy: a double-blind randomized controlled trial. Hepatology. 2022;75(5):1194-203.
-
- Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-35.
-
- Alabsawy E, Shalimar, Sheikh MF, Ballester MP, Acharya SK, Agarwal B, et al. Overt hepatic encephalopathy is an independent risk factor for de novo infection in cirrhotic patients with acute decompensation. Aliment Pharmacol Ther. 2022;55(6):722-32.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources